

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p><i>Complete if Known</i></p> <table border="1"> <tr> <td>Application Number</td> <td>10/517,881</td> </tr> <tr> <td>Filing Date</td> <td>December 13, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Robin Mark Bannister</td> </tr> <tr> <td>Art Unit</td> <td>1617</td> </tr> <tr> <td>Examiner Name</td> <td>Sahar Javanmard</td> </tr> <tr> <td>Attorney Docket Number</td> <td>GJE.7147</td> </tr> </table>		Application Number	10/517,881	Filing Date	December 13, 2004	First Named Inventor	Robin Mark Bannister	Art Unit	1617	Examiner Name	Sahar Javanmard	Attorney Docket Number	GJE.7147
Application Number	10/517,881																
Filing Date	December 13, 2004																
First Named Inventor	Robin Mark Bannister																
Art Unit	1617																
Examiner Name	Sahar Javanmard																
Attorney Docket Number	GJE.7147																
Sheet	1	of	1														

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	R1	ANGEL, I. et al., "Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT ₃ receptor antagonist and antiemetic properties," <i>European Journal of Pharmacology</i> , 1993, Vol. 232, pages 139-145.		
	R2	HOPKINS, "5-HT agonists, antagonists and uptake inhibitors," <i>Manufacturing Chemist</i> , November 1992, pages 19, 21.		
	R3	OKADA, F. et al., "Prophylactic effect of serotonin uptake inhibitors against motion sickness in <i>Suncus murinus</i> ," <i>European Journal of Pharmacology</i> , 1996, Vol. 309, pages 33-35.		
	R4	ROSLAND, J. et al., "The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations," <i>J. Pharm. Pharmacol.</i> 1990, Vol. 42, pages 437-438.		
	R5			
	R6			
	R7			
	R8			
	R9			
	R10			

Examiner Signature	/Sahar Javanmard/	Date Considered	07/16/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.